Paper Details

  1. Home
  2. Paper Details

[Systemic therapies for advanced thyroid cancer - an update].

Author: BrandenburgTim, Führer-SakelDagmar, MachlahYara Maria

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Multi-kinase inhibitors (MKIs) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. This review summarizes recent developments in the treatment of advanced thyroid cancer, including the approval of Cabozantinib for rrDTC and Selpercatinib for MTC and rrDTC.
Paper Details　
Original Abstract of the Article :
Based on phase III clinical studies, four multi-kinase inhibitors (MKI) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. Only recently, based on the randomized trial COSMIC-311, Cabozantini...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/a-1951-2902

データ提供：米国国立医学図書館（NLM）

Advanced Thyroid Cancer: Navigating the Shifting Sands of Treatment

This article, like a weathered mapmaker, provides an updated guide to systemic therapies for advanced thyroid cancer, a challenging journey through the desert of disease. The focus is on differentiated thyroid carcinoma (DTC) and medullary thyroid carcinoma (MTC), two types of thyroid cancer that can be particularly difficult to treat.

The article highlights the recent approval of new multi-kinase inhibitors (MKIs) for the treatment of progressive DTC and MTC, offering a glimmer of hope for patients with advanced disease. These MKIs target specific proteins involved in cancer growth and spread, like carefully aimed arrows striking key targets in the desert of cancer cells.

Thyroid Cancer Treatment: A Quest for Effective Therapies

This article underscores the ongoing progress in developing more effective treatments for advanced thyroid cancer. It's like a caravan of researchers constantly searching for new pathways and strategies to combat this challenging disease. The development of new drugs and treatment approaches offers hope for patients facing this diagnosis, providing a beacon of light in the desert of uncertainty.

Cancer Treatment and Personalized Care: A Personalized Journey

This article emphasizes the importance of personalized care in treating advanced thyroid cancer. It's like customizing a camel's saddle for a long and arduous journey, ensuring optimal comfort and support for the traveler. The article highlights the need for tailored treatment plans that consider the specific characteristics of each patient's cancer and their individual needs.

Dr. Camel's Conclusion

This article provides a valuable update on the treatment landscape for advanced thyroid cancer. It's like a map guiding us through the complexities of this challenging disease. The development of new drugs and treatment approaches offers hope for patients, while the emphasis on personalized care underscores the importance of individual needs in the fight against cancer.
Date :
  1. Date Completed 2023-11-06
  2. Date Revised 2023-11-27
Further Info :

Pubmed ID

37918424

DOI: Digital Object Identifier

10.1055/a-1951-2902

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.